Clinical profiles of four large pedigrees with familial dilated cardiomyopathy: Preliminary recommendations for clinical practice

Journal of the American College of Cardiology

Volumn 34, Issue 3, 1999, Pages 837-847

  Crispell, Kathy A ^a   Wray, Anita ^a   Ni, Hanyu ^a   Nauman, Deirdre J ^a   Hershberger, Ray E ^a  

^a Heart Failure Treatment Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FAMILIAL DISEASE; FEMALE; GENETIC COUNSELING; GENETIC SCREENING; HEART DILATATION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PEDIGREE; PENETRANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SUDDEN DEATH;

ADOLESCENT; ADULT; AGED; CARDIOMYOPATHY, DILATED; CHILD; CHILD, PRESCHOOL; ECHOCARDIOGRAPHY; FEMALE; GENETIC SCREENING; HUMANS; INFANT; MALE; MIDDLE AGED; OREGON; PEDIGREE; PHENOTYPE; PHYSICAL EXAMINATION; QUESTIONNAIRES;

EID: 0032852339     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00276-4     Document Type: Article

References (32)

1. Brandenburg R.O., Chazov E., Cherian G., et al. Report of the WHO/ISFC task force on definition and classification of cardiomyopathies. (abstr) Circulation. 64:1981;437-438.
2. Mestroni L., Miani D., Di Lenarda A., et al. Clinical and pathologic study of familial dilated cardiomyopathy. Am J Cardiol. 65:1990;1449-1453.
3. Michels V.V., Moll P.P., Miller F.A., et al. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med. 326:1992;77-82.
4. Baig M.K., Goldman J.H., Caforio A.P., et al. Familial dilated cardiomyopathy cardiac abnormalities are common in asymptomatic relatives and may represent early disease . J Am Coll Cardiol. 31:1998;195-201.
5. Grünig E., Tasman J.A., Kücherer H., et al. Frequency and phenotypes of familial dilated cardiomyopathy. J Am Coll Cardiol. 31:1998;186-194.
6. Krajinovic M., Pinamonti B., Sinagra G., et al. Linkage of familial dilated cardiomyopathy to chromosome 9. Am J Hum Genet. 57:1995;846-852.
7. Kass S., MacRae C., Graber H.L., et al. A gene defect that causes conduction system disease and dilated cardiomyopathy maps to chromosome 1p1-1q1. Nature Genetics. 7:1994;546-551.
8. Durand J.B., Bachinski L.L., Bieling L.C., et al. Localization of a gene responsible for familial dilated cardiomyopathy to chromosome 1q32. Circulation. 92:1995;3387-3389.
9. Olson T.M., Keating M.T. Mapping a cardiomyopathy locus to chromosome 3p22-p25. J Clin Invest. 97:1996;528-532.
10. Bowles K.R., Gajarski R., Porter P., et al. Gene mapping of familial autosomal dominant dilated cardiomyopathy to chromosome 10q21-23. J Clin Invest. 96:1996;1355-1360.
11. Messina D.N., Speer M.C., Pericak-Vance M.A., McNally E.M. Linkage of familial dilated cardiomyopathy with conduction defect and muscular dystrophy to chromosome 6q23. Am J Human Genet. 61:1997;909-917.
12. Olson T.M., Michels V.V., Thibodeau S.N., et al. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science. 280:1998;750-752.
13. Hershberger RE, Ni H, Crispell KA. Familial dilated cardiomyopathy: echocardiographic diagnostic criteria for classification of family members as affected. J Cardiac Failure 1999;5:203-12.
14. Vasan R., Larson M., Levy D., et al. Distribution and categorization of echocardiographic measurements in relation to reference limits. The Framingham Heart Study formulation of a height- and sex-specific classification and its prospective validation . Circulation. 96:1997;1863-1873.
15. Mestroni L., Krajinovic M., Severini G., et al. Familial dilated cardiomyopathy. Br Heart J. 72:1994;S35-S41.
16. Williams J., Bristow M., Fowler M., et al. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on evaluation and management of heart failure). Circulation. 92:1995;2764-2784.
17. Codd M.B., Sugrue D.D., Gersh B.J., Melton L.J. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy a population-based study in Olmsted County, Minnesota, 1975-1984 . Circulation. 80:1989;564-572.
18. Spirito P., Seidman C., McKenna W., Maron B. The management of hypertrophic cardiomyopathy. N Engl J Med. 336:1997;775-785.
19. McLatchie G.R., McKenna W.J., Hillis W.S., et al. Screening for hypertrophic cardiomyopathy (letter). Br Med J. 306:1993;860.
20. McKenna W., Spirito P., Desnos M., et al. Experience from clinical genetics in hypertrophic cardiomyopathy proposal for new diagnostic criteria in adult members of affected families . Heart. 77:1997;130-132.
21. Burn J., Camm J., Davies M.J., et al. The phenotype/genotype relation and the current status of genetic screening in hypertrophic cardiomyopathy, Marfan syndrome, and the long QT syndrome. Heart. 78:1997;110-116.
22. Roberts R., Ryan T. Task Force 3 Clinical research in a molecular era and the need to expand its ethical imperatives . J Am Coll Cardiol. 31:1998;942-949.
23. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 327:1992;685-691.
24. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med. 316:1987;1429-1435.
25. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 325:1991;293-302.
26. Cohn J., Johnson G., Ziesche S., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 325:1991;303-310.
27. Garg R., Yusuf S. Overview of randomized trials of angiotensin converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 273:1995;1450-1456.
28. Colucci W.S., Packer M., Bristow M.R., et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation. 94:1996;2800-2806.
29. Bristow M.R., Gilbert E.M., Abraham W.T., et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 94:1996;2807-2816.
30. Packer M., Bristow M.R., Cohn J., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334:1996;1349-1355.
31. Urbina E.M., Gidding S.S., Bao W., et al. Effect of body size, ponderosity, and blood pressure on left ventricular growth in children and young adults in the Bogalusa Heart Study. Circulation. 91:1995;2400-2406.
32. Nidorf S., Picard M., Triulzi M., et al. New perspectives in the assessment of cardiac chamber dimensions during development and adulthood. J Am Coll Cardiol. 19:1992;983-988.